- Record: found
- Abstract: not found
- Article: not found
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J. Antonia
1 ,
Augusto Villegas
1 ,
Davey Daniel
1 ,
David Vicente
1 ,
Shuji Murakami
1 ,
Rina Hui
1 ,
Takayasu Kurata
1 ,
Alberto Chiappori
1 ,
Ki H. Lee
1 ,
Maike de Wit
1 ,
Byoung C. Cho
1 ,
Maryam Bourhaba
1 ,
Xavier Quantin
1 ,
Takaaki Tokito
1 ,
Tarek Mekhail
1 ,
David Planchard
1 ,
Young-Chul Kim
1 ,
Christos S. Karapetis
1 ,
Sandrine Hiret
1 ,
Gyula Ostoros
1 ,
Kaoru Kubota
1 ,
Jhanelle E. Gray
1 ,
Luis Paz-Ares
1 ,
Javier de Castro Carpeño
1 ,
Corinne Faivre-Finn
1 ,
Martin Reck
1 ,
Johan Vansteenkiste
1 ,
David R. Spigel
1 ,
Catherine Wadsworth
1 ,
Giovanni Melillo
1 ,
Maria Taboada
1 ,
Phillip A. Dennis
1 ,
Mustafa Özgüroğlu
1
September 25 2018
September 25 2018
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged
progression-free survival, as compared with placebo, among patients with stage III,
unresectable non-small-cell lung cancer (NSCLC) who did not have disease progression
after concurrent chemoradiotherapy. Here we report the results for the second primary
end point of overall survival.